

UNITED STATES PATENT AND TRADEMARK OFFICE

Construssioner for Patents, Box FC L United States Patrit and Fradminis Office Washington, D.C., 2023

U.S. APPLICATION NUMBER NO FIRST NAMED APPLICANT ATTY DOCKET NO 09/857.008 Jean Herscovici ST98046 US PCT INTERNATIONAL APPLICATION NO 005487 PCT/FR99/02995 AVENTIS PHARMACEUTICALS, LNC LA FILING DATE PRICRITY DATE PATENTS DEPARTMENT 12/02/1999 ROUTE 202-206, P.O. BOX 6800 BRIDGEWATER, NJ 08807-0800 CONFIRMATION NO. 9262 **371 FORMALITIES LETTER** OC000000007320933

Date Mailed: 01/25/2002

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):


- U.S. Basic National Fee
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Oath or Declaration
- Preliminary Amendments

The following items MUST be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

- Oath or declaration of the inventors, in compliance with 37 CFR 1.497(a) and (b), identifying the application by the International application number and international filing date. The current oath or declaration does not comply with 37 CFR 1.497(a) and (b) in that it:
 - is not executed in accordance with either 37 CFR 1.66 or 37 CFR 1.68.
- \$130 Surcharge for providing the oath or declaration later than the appropriate 30 months months from the priority date (37 CFR 1.492(e)) is required.
- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with THE HER OF OF SECTION AND EFFECTIVE FOR THE PROPERTY

 An initial or substitute paper copy or compact discut the Conjuntum costing in a submit as a amendment directing its entry into the specification.





PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

HERSCOVICI ET AL.

Serial No.: 09/857,008

Filed:

MAY 30, 2001

Title:

NOVEL NUCLEIC ACID TRANSFERRING AGENTS,

COMPOSITIONS CONTAINING

THEM AND USES

Examiner:

NOT ASSIGNED

Art Unit:

NOT ASSIGNED

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

February 11, 2002

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

Commissioner for Patents Washington, D.C. 20231

Attention:

Ms. Christine S. Washington

Dear Ms. Washington:

On January 25, 2002, you issued a Notice of Defective Response (Notice) in connection with the above-identified Application. In the Notice, you asserted that the following must be submitted in order to complete the requirements for acceptance under 35 U.S.C. § 371:

- an executed oath or declaration;
- a substitute paper copy or compact disc of the "Sequence Listing"; and (b)
- an amendment directing entry of the substitute "Sequence Listing" into the Specification of the above-(c) identified Application.

Kindly note that our records show that an executed declaration filed with the USPTO on 23 October

2001. Hence, in response to this Notice, we submit herewith the following:

- a paper copy of a substitute "Sequence Listing"; (a)
- a diskette containing a computer readable form of the substitute "Sequence Listing"; (b)
- a Statement pursuant to 37 CFR 1.821; (c)
- (d) a preliminary amendment directing entry of the substitute "Sequence Listing" into the specification;
- a copy of the executed Declaration for the above-identified Application that was filed with the United (e) States Patent and Trademark Office on 23 October 2001;

The Advisor distriction was filled with the USPTO, and the USPTO's

Aventis Pharmaceuticals Inc Patent Department Reute #202-206 / P.O. Box 6800



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of

HERSCOVICE ET AL.

Serial No.: 09/857,008

Filed:

MAY 30, 2001

Title:

NOVEL NUCLEIC ACID
TRANSFERRING AGENTS,
COMPOSITIONS CONTAINING

THEM AND USES

Examiner:

NOT ASSIGNED

Art Unit:

NOT ASSIGNED

1 hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231, on

August 15, 2002

Signature

Signature

RESPONSE TO NOTIFICATION OF DEFECTIVE RESPONSE

Commissioner for Patents Washington, D.C. 20231

Attention:

Ms. Christine S. Washington

Dear Ms. Washington:

On January 25, 2002, you issued a Notice of Defective Response (Notice) in connection with the above-identified Application. On February 11, 2002 (coplicants responded timely to the Notice.

On August 9, 2002, a second Notice of Defective Response dated January 25, 2002 was received. This Notice indicated that the diskette previously filed in this matter was damaged, and a request was made an initial or substitute paper or compact diskette of the Sequence Listing and a preliminary amendment directing entry of the Sequence Listing into the instant Specification. During a telephone conference between Examiner Kim at the PCT help desk and the undersigned held on August 14, 2002. Examiner Kim explained he would recall the file for this Application from the PCT processing center, and instructed the undersigned to respond to the second notice. Hence, Applicants file herewith:

- (a) a second paper copy of a substitute "Sequence Listing";
- (b) a second diskette containing a computer readable form of the substitute "Sequence Listing";
- (c) a second Statement pursuant to 37 CFR 1.821;

No fees are believed to be necessitated by the instant response. However, should this be in error, authorization is hereby given to charge Deposit Account no. 18-1982 for any underpayment, or to credit any overpayments.

Respectfully submitted.

William C. Coppola, Reg. No. 41,686

Aventis Pharmaceuticals Inc.
Patent Department
Route #202-206 / P.O. Box 6800
Bridgewater, New Jersey 08807-0800
Aventis Docket No. ST98046 US PCT
August 15, 2002